Top-News

UCB S.A. UNSP.ADR 1/2 Aktie News

Aktie
WKN:  A14WZY ISIN:  US9034801012 US-Symbol:  UCBJY Branche:  Biotechnologie Land:  Belgien
123,50 €
+0,00 €
0,00%
10:39:26 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
100,00%
KGV
34,49
Dividende
0,46 $
Dividendenrendite
0,32%
Index-Zuordnung
-

UCB S.A. UNSP.ADR 1/2 News

17.09.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
BIMZELX® (bimekizumab-​bkzx) New Three-​year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints PR Newswire
17.09.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
BIMZELX® (bimekizumab-​bkzx) Data in Moderate-​to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years PR Newswire
10.09.25 - PR Newswire
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care PR Newswire
29.08.25 - PR Newswire
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress PR Newswire
29.08.25 - PR Newswire
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress PR Newswire
05.08.25 - PR Newswire
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment PR Newswire
08.07.25 - PR Newswire
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
UCB extends its BIMZELX® "Get Yourself Back" direct-​to-consumer campaign for the hidradenitis suppurativa community PR Newswire
27.06.25 - PR Newswire
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder PR Newswire
20.06.25 - PR Newswire
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference PR Newswire
17.06.25 - PR Newswire
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S. PR Newswire
12.06.25 - PR Newswire
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity PR Newswire
11.06.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
BIMZELX® (bimekizumab-​bkzx) Three-​Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis PR Newswire
19.05.25 - PR Newswire
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences PR Newswire
03.04.25 - PR Newswire
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025 PR Newswire
19.03.25 - PR Newswire
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference PR Newswire
12.03.25 - PR Newswire
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
Epilepsia Publishes Final Analysis of Open-​Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome ...
07.03.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
BIMZELX® (bimekizumab-​bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-​to-Severe Plaque Psoriasis PR Newswire
07.03.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
BIMZELX® (bimekizumab-​bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden PR Newswire
27.02.25 - PR Newswire
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth PR Newswire
16.01.25 - PR Newswire
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
UCB Announces U.S. Availability of 320 mg/2 mL Single-​Injection Administration Option for BIMZELX® (bimekizumab-​bkzx) PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »